Supplemental Text from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Author/s
author: Andreas Varkaris, Adam Frost, Fabrizio Giordanetto, Erika Hamilton, Michael J Holliday, Jonathan R LaRochelle, Brenton G Mar, Yakov Pechersky, Erika G Puente, Ramin Samadani, Alison M Schram, Shahein Tajmir, Patrick Walters, David E. Shaw, James S Fraser, D Randal Kipp
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.